Hence, a loss of PI(3,5)P2 sensitivity is characteristic of the HOD-causing CLCN7 mutations known till date, and increased sensitivity to polyphosphoinositides is observed in some, but not all, osteopetrosis-associated accelerated gating mutants. This evidence concerns the gene CLCN7 and hypopigmentation, organomegaly, and delayed myelination and development.